首页> 外文期刊>Journal of public health policy >Whistleblowing in the pharmaceutical industry in the United States, England, Canada, and Australia.
【24h】

Whistleblowing in the pharmaceutical industry in the United States, England, Canada, and Australia.

机译:在美国,英国,加拿大和澳大利亚的制药行业进行举报。

获取原文
获取原文并翻译 | 示例
       

摘要

Fraud and abuse in the spending of public monies plague governments around the world. In the United States the False Claims Act encourages whistleblowing by private individuals to expose evidence of fraud. They are rewarded for their efforts with monetary compensation and protection from retaliation. Such is not the case in Canada, England, and Australia. Although some recent legislation has increased the protections afforded to whistleblowers, they are still likely to be viewed more as disloyal employees than courageous public servants, and there is little incentive to risk their jobs and reputation. Qui tam laws provide a police force of thousands in the effort to reduce rampant fraud, waste, and abuse, and would be an asset in any health-care system where pubic health policy requires conservation of resources.
机译:公款支出中的欺诈和滥用困扰着世界各地的政府。在美国,《虚假索赔法》鼓励私人举报以揭露欺诈证据。他们因付出金钱补偿和免受报复的努力而获得回报。在加拿大,英国和澳大利亚情况并非如此。尽管最近的一些立法增加了对举报人的保护,但他们仍然被看做是不忠实的雇员,而不是勇敢的公务员,并且几乎没有动机来冒险举报他们的工作和声誉。基坦法律提供了数千名警察,以减少猖in的欺诈,浪费和滥用,这将成为任何公共卫生政策需要节约资源的医疗体系的资产。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号